Oruka Therapeutics, INC Form 4 insider transactions

Paul T Quinlan, General Counsel of Oruka Therapeutics, Inc., sold 52,000 shares of common stock on August 14, 2026.

Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics, Inc., sold 10,000 shares of common stock on August 13, 2026.

Joana Goncalves, Chief Medical Officer of Oruka Therapeutics, Inc., sold 7,000 shares of common stock on July 15, 2026.

Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics, Inc., sold 9,999 shares of common stock on July 13, 2026.

Fairmount Funds Management LLC, along with affiliated entities, has converted a significant portion of Series B Preferred Stock into common stock of Oruka Therapeutics, Inc.

Laura Lee Sandler, Chief Operating Officer of Oruka Therapeutics, Inc., reported transactions involving the acquisition and disposition of company common stock.

Senior Vice President of Finance Arjun Agarwal exercised stock options and sold shares of Oruka Therapeutics under a 10b5-1 plan.

Oruka Therapeutics Chief Medical Officer Joana Goncalves exercised stock options and sold shares under a 10b5-1 plan.

CEO Lawrence Klein sold 1,729 shares of Oruka Therapeutics to satisfy tax obligations related to RSU vesting.

Oruka Therapeutics Chief Operating Officer Laura Lee Sandler sold 600 shares of common stock to satisfy tax obligations.

General Counsel Paul T. Quinlan sold 733 shares of Oruka Therapeutics to satisfy tax obligations related to RSU vesting.

Director Carl Dambkowski sold 35,000 shares of Oruka Therapeutics, Inc. common stock via a pre-arranged 10b5-1 trading plan.

Oruka Therapeutics Director Carl Dambkowski acquired stock options for 9,136 shares of common stock.

Oruka Therapeutics Director Samarth Kulkarni acquired stock options for 9,136 shares, with vesting commencing June 2, 2026.

Oruka Therapeutics Director Christopher Martin acquired stock options for 9,136 shares of common stock.

Kristine M. Ball, a Director at Oruka Therapeutics, Inc., acquired stock options for 9,136 shares.

Fairmount Funds Management LLC and associated entities report the grant of stock options to a director, with vesting commencing June 2, 2026.

Oruka Therapeutics Director Carl Dambkowski executed a series of option exercises and stock sales totaling 105,000 shares under a pre-arranged trading plan.

Arjun Agarwal, Senior Vice President of Finance at Oruka Therapeutics, exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Chief Medical Officer Joana Goncalves exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Oruka Therapeutics Chief Operating Officer Laura Lee Sandler exercised 5,000 stock options and sold 5,000 shares under a pre-arranged 10b5-1 trading plan.

Chief Medical Officer Joana Goncalves exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Oruka Therapeutics CEO Lawrence Klein sold 1,729 shares of common stock at $41.3 per share to cover tax withholding obligations.

Oruka Therapeutics' Senior Vice President of Finance, Arjun Agarwal, sold 395 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Oruka Therapeutics' Chief Operating Officer, Laura Lee Sandler, sold 600 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Oruka Therapeutics' Chief Medical Officer, Joana Goncalves, reported exercising stock options and warrants while selling common stock, including shares under a 10b5-1 plan and for tax obligations.

Oruka Therapeutics' General Counsel, Paul T. Quinlan, sold 733 shares of common stock at $41.3 per share to cover tax withholding obligations related to restricted stock unit vesting.

Oruka Therapeutics' Chief Operating Officer, Laura Sandler, exercised options and subsequently sold an equivalent number of shares under a pre-arranged trading plan.

Oruka Therapeutics' Chief Medical Officer, Joana Goncalves, reported the acquisition of 32,500 common shares and 130,000 employee stock options.

Oruka Therapeutics' Chief Operating Officer, Laura Lee Sandler, received grants of 32,500 common shares and options for 130,000 shares.